pharmaphorum6y
FDA rejects GSK's Nucala in COPD, asking for more clinical data
The US regulator has rejected GlaxoSmithKline's pulmonary disease drug Nucala in a potential new chronic obstructive pulmonary disease (COPD) use. In July, Nucala (mepolizumab), which is already ...
Hosted on MSN20d
GSK’s Nucala approved in China as add-on therapy for adults with CRSwNP
GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that targets interleukin-5, ...
pharmaphorum4y
GSK eyes nasal polyps use for Nucala after trial success
GlaxoSmithKline is eyeing another indication for its Nucala (mepolizumab) biologic drug after a phase 3 trial in inflammation caused by nasal polyps hit its targets, bringing it into competition ...
Business Insider20d
GSK’s Nucala Gains Approval in China for CRSwNP
GlaxoSmithKline ( (GSK)) has provided an update ... Investor Newsletter GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with ...
GlobalData on MSN17d
China’s NMPA approves GSK’s Nucala for CRSwNP treatment
The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with nasal ...
Nasdaq1mon
GSK: FDA Accepts For Review Submission For New Indication Of Nucala In COPD
The submission seeks an indication for the use of Nucala as an add-on maintenance treatment for patients with COPD with an eosinophilic phenotype. The Prescription Drug User Fee Act (PDUFA ...
Medical News Today11d
Nucala administration
Nucala (mepolizumab) is a brand-name subcutaneous injection that comes in different forms. Depending on which form you’re prescribed, you or your doctor will administer the injection. Nucala ...
GSK's Sinus Disease Drug Secures Approval In China
On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on therapy with intranasal corticosteroids for adult patients with chronic ...
Mint24d
Glaxosmithkline Pharmaceuticals share price
GlaxoSmithKline Pharmaceuticals Limited is ... Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic ...
Yahoo Finance20d
GSK’s Nucala Gains Approval in China for CRSwNP
GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been ... type 2 inflammation-related diseases. More about GlaxoSmithKline GSK is a global biopharmaceutical company dedicated ...
Business Insider20d
GSK’s Nucala approved in China as add-on therapy for adults with CRSwNP
GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that targets interleukin-5, as an add-on therapy with intranasal ...